Natco Pharma’s Hyderabad pharma division has received Establishment Inspection Report (EIR) classifying the facility as Voluntary Action Indicated (VAI) from the U.S. Food and Drug Administration (USFDA).
Earlier, U.S. Food and Drug Administration (USFDA) had conducted an inspection at its Pharma division located in Kothur, Hyderabad, India.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.
